Group items tagged

Teva UK has begun replacing its existing packaging with a new design which is "clearer and easier to read". The new look is "unique, recognisable and distinctive." It "enhances safety and provides a recognisable and distinguishable pack range." One of the UK's leading generics manufacturers, Teva UK supplies more than 500 generic pharmaceutical products to retail and hospital pharmacies. The company says each product within the portfolio is distinguishable by colour, ensuring no two different packs have the same drug and strength colours and with additional product information on the side of the pack and a simplified back, it makes it even easier to identify the correct product when dispensing and supports patients when taking their medication. "Our medicines impact the lives of millions of people every day and our packaging is often the first touchpoint for our patients and our customers", said Kim Innes, general manager of Teva UK and Ireland.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a second "bivalent" vaccine as a Covid-19 booster. The updated booster vaccine made by Pfizer/BioNTech, targeting two coronavirus variants, has been approved for use in individuals aged 12 years and above. In each dose of the booster vaccine, 'Comirnaty bivalent Original/Omicron', half of the vaccine (15 micrograms) targets the original virus strain and the other half (15 micrograms) targets Omicron (BA.1). Dr June Raine, MHRA chief executive said: "I am pleased to announce that we now have a second approved vaccine for the UK Autumn booster programme. The clinical trial of the Pfizer/BioNTech bivalent vaccine showed a strong immune response against the Omicron BA.1 variant as well as the original strain. Bivalent vaccines are helping us to meet the challenge of an ever-evolving virus, to help protect people against Covid-19 variants. We have in place a comprehensive safety surveillance strategy for all UK-approved Covid-19 vaccines, and this will include the updated booster we approved today."

Pharmacy wholesaler PHOENIX UK is investing over £13 million to build a new state-of-the-art distribution hub in Wakefield. The 260,000 sq. ft facility is expected to be operational next year and will service community pharmacies, hospitals and dispensing doctors across the North East of England and Yorkshire. In a statement on Tuesday (July 5), PHOENIX UK said the completed hub will feature 22 dock level loading bays and seven access doors to enable the productive arrival and distribution of medical products. It will also be highly energy efficient, including the use of Solar PV on its roof. The car park will also offer 46 electric vehicle charging bays. Speaking at an official opening event held on 30 June to mark the expansion of the company's distribution capabilities, group managing director of PHOENIX Steve Anderson said: "Over the last few years, we have seen an outstanding growth in customer demand for our core services outpacing the market: Wakefield is a prime example of how we are committed to investing in the future by expanding our UK-wide operational capabilities to offer all our customers across the country the best possible service they need, want and deserve.

Teva UK has alerted the Secretary of State for Health and Social Care to the problem posed by steep energy prices. Teva's UK General Manager Kim Innes wrote to the minister seeking assurances that the distribution of medicines to patients will be safeguarded over what's likely to be a difficult winter. The problems posed by steep energy prices and the potential for power rationing is putting pharmacies under pressure from increased costs and the risk of losing power supplies as a 'non-domestic' energy user, said the company. Kim said: "In our letter to the Secretary of State we acknowledged that the government knows that medicines manufacture is strategically important and that it's a vital component in maintaining patient health." "But I wanted to make sure that the Secretary of State also realises the consequences of the energy crisis further down the supply chain - for example, the need for a pharmacy to have a fridge switched on at all times for storing cold chain products."

Bestway operates approximately 750 pharmacies nationwide in the UK under the Well brand. In April 2023, it completed its acquisition of Lexon, which operates 46 pharmacies in the UK under the Knights Pharmacy brand, and Asurex, a wholesale perfume supplier. On 26th May 2023, CMA announced the launch of its merger inquiry. A fast-track Phase 1 investigation found that the merger could lead to a significant lessening of competition between retail pharmacies in 12 local areas located in Liverpool and North East England. The merging businesses conceded that the deal raises competition concerns in these areas and have submitted proposals to sell pharmacies within these areas to restore the competition that would otherwise be lost as a result of the deal. Colin Raftery, CMA Senior Director of Mergers, said: "Pharmacies are essential public health services, and it's vital that the loss of competition brought about by a deal like this shouldn't leave people with reduced choice or worse services when they need medical support. The CMA will now carefully consider whether the remedy put forward by Bestway will address its concerns and ensure that customers in the affected areas continue to have access to good quality chemists.

Professional leadership bodies from around the world discussed workforce shortages in community pharmacy and other challenges affecting the sector at a global meeting held in Paris last month. Delegated from Denmark, Australia, Ireland, New Zealand, Portugal, Spain, US and the UK updated the conference on how the profession was progressing in practice, technology and workforce development in their respective countries. The UK was represented at World Pharmacy Council meeting by National Pharmacy Association chair Andrew Lane and chief executive at the Pharmaceutical Services Negotiating Committee Janet Morrison. Lane said: "It's very useful to be part of a global network of pharmacy bodies who are all going through similar challenges as we are in the UK. Sharing intelligence on other pharmacy systems around the world helps us to prepare the right strategy for engaging with the NHS at home. "Hearing some of the strides in services and digital technology in the profession gives us hope for the future of the sector. It's clear however that key challenges such as workforce shortages are starting to have an effect in other parts of the world too."

The UK government has announced plans to update legislation to enable more services and individuals to provide take-home supplies of naloxone - a life-saving opioid overdose antidote - over the next few weeks. Naloxone can immediately reverse the effects of an opioid overdose by reversing breathing difficulties. The medicine can be administered by anyone in an emergency. However, current legislation allows only drug and alcohol treatment services to supply it without a prescription to individuals for future use. The Department of Health and Social Care (DHSC) confirmed on Tuesday (14 May) that more professionals, including nurses, paramedics, police officers, probation officers and pharmacy professionals, will be able to supply the medicine without a prescription to save lives. Health and Social Care Secretary Victoria Atkins warned that opioid addiction can ruin lives and it accounts for the largest proportion of drug-related deaths across the UK.

The Pharmaceutical Services Negotiating Committee (PSNC) has published an update on the work it is doing as part of the Transforming Pharmacy Representation (TAPR) Programme to take forward the mandate from contractors to deliver the Review Steering Group (RSG) recommendations. The update is primarily aimed at LPCs - with whom PSNC has been working closely on some of the TAPR work over the summer. The TAPR Programme is being undertaken in support of PSNC's work to address the severe challenges facing the community pharmacy sector at present. Alongside ongoing negotiations with Government and the NHS, two of the TAPR workstreams - focusing on Vision and Strategy, and on Influencing and Negotiation - are essential to supporting CPCF negotiations. "The workstreams are looking at the future of community pharmacy and how best to persuade policymakers to implement a shared vision, with their objective being to put the sector in a stronger position going into future CPCF negotiations," said PSNC.

Covid-19 booster jab can now be administered sooner than six months after the second dose to certain vulnerable people as guideline in the UK Health Security Agency (UKHSA) Green Book has been updated. With the change in the guidance, care home residents who have been given their second vaccine dose at different times will be able to be jabbed in the same session, as long as it has been at least five months since their last dose. It may also help with other vulnerable groups, such as housebound patients to have their flu and Covid-19 vaccines at the same time. The move will also benefit those who are about to receive immunosuppressive treatment as they can get the booster from a minimum of four months after their second dose. Health secretary Sajid Javid said: "This updated guidance will ensure healthcare professionals have the necessary flexibility in the booster programme, allowing more vulnerable people to be vaccinated where it makes operational sense to do so." Vaccines minister Maggie Throup also encouraged eligible people to book their booster jab and secure protection.

The government has launched a consultation into radically changing the Statutory Scheme for branded medicines (known as the Statutory Scheme). The consultation comes as delicate negotiations for replacing the alternative Voluntary Scheme are underway, potentially undermining these talks, while also further damaging industry confidence in the UK as a viable place to research, launch and supply medicine. The government proposals seek to hold average revenue clawback rates under the Statutory Scheme at historic highs of between 21-27%, compared to the pre-pandemic averages of 9.4% for the Statutory Scheme (2019-2021), and 6.88% for the Voluntary Scheme (2014-2021). The accompanying cost-benefit analysis ignores any negative impact this may have on medicine supply and wrongly claims it will boost investment. The consultation comes on the heels of government data last week showing UK life sciences foreign direct investment (FDI) fell by 47% between 2021 and 2022, down by £900m year on year. This large fall in investment coincided with a rise in the main UK clawback rate under the Voluntary Scheme from 5% to 15%, and led to the UK falling from 2nd to 9th out of 18 comparator countries for life sciences FDI in 2022. The Voluntary Scheme clawback rate now sits at a record 26.5% in 2023.

The Department of Health and Social Care (DHSC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) have added five more medicines that cannot be hoarded or exported from the UK market. The government has taken the following action to address the "critical shortage" of attention deficit hyperactivity disorder (ADHD) drugs. In a crucial development on October 9, this strategic move aims to enable wholesalers to fulfil their legal obligation to supply these essential medicines to patients across the UK. The updated list of drugs incorporated "all" available strengths and pharmaceutical formulations, ensuring comprehensive coverage for patients' medical needs.

US biotech firm Moderna will build a new research and manufacturing centre in Britain to develop vaccines against new Covid-19 variants, other respiratory illnesses and help improve readiness for any future pandemics. The facility is expected to start producing shots in 2025 and Britain has made a commitment to buy Moderna's vaccines for the next decade under the agreement. Moderna's Covid-19 vaccines, which use messenger RNA (mRNA) technology, were among those deployed in Britain to tackle the crisis and enable prime minister Boris Johnson to reopen the economy from stringent lockdowns. Moderna chief executive Stephane Bancel said the priority was to develop a shot combining refreshed boosters against Covid, flu and Respiratory Syncytial Virus (RSV). "By building a plant in the UK, we are also providing the UK Government - which has a long term partnership with us, with this agreement - with the ability to be pandemic ready," Bancel said on Wednesday.

The UK Health Security Agency on Friday said it had designated a sub-lineage of the dominant and highly transmissible Omicron coronavirus variant as a variant under investigation. BA.2, which does not have the specific mutation seen with Omicron that can be used as a proxy to easily distinguish it from Delta, is being investigated but has not been designated a variant of concern. "It is the nature of viruses to evolve and mutate, so it's to be expected that we will continue to see new variants emerge," Dr Meera Chand, incident director at the UKHSA, said. "Our continued genomic surveillance allows us to detect them and assess whether they are significant." Britain had identified 53 sequences of the BA.2 sub-lineage as of January 10, with updated figures due to be published later on Friday.

The National Institute for Health and Care Excellence (NICE) has issued draft guidance on 'Evusheld' which is not recommended for vulnerable adult with high risk of severe Covid-19 on Thursday (16 February). The draft guidance is open for public consultation until 9 March 2023. The committee will consider any comments received at a meeting currently due to take place on 4 April 2023. It comes after last month's decision by the US drug regulator to withdraw its emergency use authorisation for Evusheld as a preventative treatment for Covid-19, which said there was insufficient evidence that Evusheld is effective against the dominant variants of Covid-19 in the US. NICE's independent appraisal committee has reached the same conclusion having considered evidence which shows Evusheld is unlikely to prevent infection with most of the variants circulating in the UK now and in the near future. It has also announced that it is developing a new review process to update recommendations on the cost-effectiveness of Covid-19 treatments so they can be made available more quickly to patients if they show promise against new variants and are found to be cost-effective.

he British Generic Manufacturers Association (BGMA) has voted Pete Kelly, managing director of Accord UK, to become its new chair. He replaces Peter Ballard, who has completed his second tenure as the association's chair and will now serve a further year as vice-chair. Pete leads the UK operations of Accord, one of the largest generic and biosimilar manufacturers in Europe. In the UK, the company currently supplies a fifth of all generic medicines. Mark Samuels, chief executive of BGMA, said: "We are very fortunate to have someone of Pete's experience and leadership qualities to take on the mantle of chair of the association. The industry faces a challenging period on many fronts, and Pete's input will be invaluable. "I would also like to record my enormous gratitude to Peter Ballard, our out-going Chair who has been an incredible servant to the association over many, many years. He will continue for another year as vice-chair, and we are pleased to have his continuing advice."

Balmedie Pharmacy based in Aberdeenshire, Scotland has been purchased by local expanding multiple operator JMF Healthcare. Balmedie Pharmacy is a well-performing community pharmacy that dispenses an average of 5,255 items per month. It lies completely unopposed in the large Aberdeenshire village of Balmedie, which is circa eight miles north of Aberdeen City Centre. The pharmacy has been owned by Brian Arris since 2004 and was recently brought to market to allow him to pursue other pharmacy business opportunities. Following a confidential sales process with Christie & Co, JMF Healthcare to benefit from new housing developments in this area of Aberdeenshire such as 300 new homes planned in Balmedie, approved plans for up to 500 new homes in Trump Menie Estate, and 284 new homes planned in Blackdog Village. Brian Arris, previous owner of Balmedie Pharmacy, comments, "I'm sad to see the business go as the excellent staff have helped grow the pharmacy from scratch since 2004 and we've all put our hearts and souls into providing good pharmaceutical care for the village and surrounding area. I'm confident everyone is left in safe hands with John at the helm now."

Nine more new products have been classed as 'Drugs for which Discount is Not Deducted' (DND) from 1 July 2022, announced Department of Health and Social Care (DHSC). This takes the total number of products granted DND status over the past 2 years to over 500 following checks made by the Pharmaceutical Services Negotiating Committee. The Committee had made an application to DHSC and NHSBSA for the following 9 products to be added to the DND list of Individual items to which the discount deduction scale will no longer apply from July 2022: Fludrocortisone 50micrograms/5ml oral suspension (Group) Lorazepam 1mg/5ml oral suspension (Group) Lorazepam 500micrograms/5ml oral suspension (Group) Zopiclone 3.75mg/5ml oral solution (Group) Zopiclone 7.5mg/5ml oral solution (Group) GA explore5 oral powder 12.5g sachets HCU explore5 oral powder 12.5g sachets MSUD explore5 oral powder 12.5g sachets TYR explore5 oral powder 12.5g sachets The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff.

A group of drugs commonly used to treat erectile dysfunction may be able to boost the effect of chemotherapy in oesophageal cancer, according to new research funded by Cancer Research UK and the Medical Research Council. The research, published on Tuesday (June 22) in Cell Reports Medicine, found that the drugs, known as PDE5 inhibitors can reverse chemotherapy resistance by targeting cells called cancer-associated fibroblasts (CAFs) residing in the area surrounding the tumour. Although this is early discovery research, PDE5 inhibitors combined with chemotherapy, may be able to shrink some oesophageal tumours more than chemotherapy could alone, tackling chemotherapy resistance, which is one of the major challenges in treating oesophageal cancer. Oesophageal cancer affects the food pipe that connects the mouth to the stomach, and while it is a relatively rare cancer, the UK has one of the higher rates in the world, with 9,300 new oesophageal cancer cases in the UK every year. Resistance to chemotherapy in oesophageal cancer is influenced by the tumour microenvironment, the area that sounds the tumour. This is made up of molecules, blood vessels, and cells such as cancer associated fibroblasts (CAFs), which are important for tumour growth. It feeds the tumour and can act as a protective cloak, preventing treatments like chemotherapy from having an effect.

The Association of the British Pharmaceutical Industry (ABPI) today released a new guidance to pharmaceutical companies using Disclosure UK which it said will boost transparency in the relationships between healthcare professionals, other relevant decision-makers and the industry. The guidance encourages companies to use 'Legitimate Interests' as their lawful basis for processing individual's data, in order to increase the number of named healthcare professionals and other individuals on Disclosure UK, the database showing the payments and benefits in kind made by the pharmaceutical industry to doctors,nurses and other health professionals and organizations. "I'm pleased the ABPI is launching this new guidance which will boost patient safety and public confidence in our healthcare professionals," Patient Safety and Primary Care Minister Maria Caulfield commented.

The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair. DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly. With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca. She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services. In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to prepare for the proposed spin out of the company from its parent, Novartis, expected later this year. She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing the sustainability of our industry so we can continue to play our vital part in the health of the nation." Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through her role on the BGMA board and leadership of a key strategic committee.